| Company | Sector & Purpose | Updated | Following |
|---|---|---|---|
|
Amgen
|
Biotechnology
To serve patients by transforming the promise of science and biotechnology into therapies with the potential to restore health or save lives
|
2025-Q3
|
|
|
Alnylam Pharmaceuticals
|
Biotechnology
To transform the lives of people afflicted with rare genetic diseases by translating RNA interference into a whole new class of innovative medicines
|
2025-Q3
|
|
|
Adaptive Biotechnologies
|
Biotechnology
Translate the genetics of the adaptive immune system into clinical diagnostics and therapeutics
|
2025-Q3
|
|
|
Adma Biologics
|
Biopharmaceuticals
To manufacture, market and develop specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases
|
2025-Q3
|
|
|
Arcus Biosciences
|
Biotechnology
To develop innovative cancer immunotherapies that transform patient outcomes through precision medicine approaches
|
2025-Q3
|
|
|
Adc Therapeutics Sa
|
Biotechnology
To develop and deliver innovative antibody drug conjugates to transform treatment for cancer patients globally
|
2025-Q3
|
|
|
Allogene Therapeutics
|
Biotechnology
To develop transformative allogeneic CAR T cell therapies to treat cancer patients
|
2025-Q3
|
|
|
Arcellx
|
Biotechnology
To develop innovative cell therapies for cancer patients using advanced biotechnology platforms
|
2025-Q3
|
|
|
4d Molecular Therapeutics
|
Biotechnology
To transform medicine by advancing next-generation gene therapies using novel AAV vectors to treat genetic diseases
|
2025-Q3
|
|
|
Annexon
|
Biotechnology
To develop innovative complement-targeted therapeutics for patients with classical complement-mediated autoimmune and neurodegenerative diseases
|
2025-Q3
|
|
|
Belief Biomed
|
Biotech
To develop breakthrough therapeutics for rare diseases using innovative AI-driven drug discovery platforms
|
2025-Q3
|
|
|
Apogee Therapeutics
|
Biotechnology
To develop transformative immunology medicines for patients with serious diseases
|
2025-Q3
|